Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.

Details

Serval ID
serval:BIB_30B9633467AB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.
Journal
World journal of urology
Author(s)
Kaufmann E., Aeppli S., Arnold W., Balermpas P., Beyer J., Bieri U., Cathomas R., de Bari B., Dressler M., Engeler D.S., Erdmann A., Gallina A., Gomez S., Guckenberger M., Herrmann TRW, Hermanns T., Ilaria L., John H., Kessler T.M., Klein J., Laouiti M., Lauffer D., Mattei A., Müntener M., Nguyen D., Niederberger P., Papachristofilou A., Prause L., Reinhardt K., Salati E., Sèbe P., Shelan M., Strebel R., Templeton A.J., Vogl U., Wettstein M.S., Zihler D., Zilli T., Zwahlen D., Roth B., Fankhauser C.
ISSN
1433-8726 (Electronic)
ISSN-L
0724-4983
Publication state
Published
Issued date
19/09/2024
Peer-reviewed
Oui
Volume
42
Number
1
Pages
527
Language
english
Notes
Publication types: Journal Article ; Systematic Review
Publication Status: epublish
Abstract
Optimal follow-up strategies following trimodal treatment for muscle invasive bladder cancer play a crucial role in detecting and managing relapse and side-effects. This article provides a comprehensive summary of the patterns and risk factors of relapse, functional outcomes, and follow-up protocols.
A systematic literature search on PubMed and review of current guidelines and institutional follow-up protocols after trimodal therapy were conducted.
Out of 200 identified publications, 43 studies (28 retrospective, 15 prospective) were selected, encompassing 7447 patients (study sizes from 24 to 728 patients). Recurrence rates in the urinary bladder varied between 14-52%; 3-16% were muscle-invasive while 11-36% were non-muscle invasive. Nodal recurrence occurred at 13-16% and distant metastases at 15-35%. After 5 and 10 years of follow-up, around 60-85% and 45-75% of patients could preserve their bladder, respectively. Various prognostic risk factors associated with relapse and inferior survival were proposed, including higher disease stage (> c/pT2), presence of extensive/multifocal carcinoma in situ (CIS), hydronephrosis, multifocality, histological subtypes, incomplete transurethral resection of bladder tumor (TURBT) and incomplete response to radio-chemotherapy. The analyzed follow-up guidelines varied slightly in terms of the number, timing, and types of investigations, but overall, the recommendations were similar.
Randomized prospective studies should focus on evaluating the impact of specific follow-up protocols on oncological and functional outcomes following trimodal treatment for muscle-invasive bladder cancer. It is crucial to evaluate personalized adaption of follow-up protocols based on established risk factors, as there is potential for improved patient outcomes and resource allocation.
Keywords
Humans, Urinary Bladder Neoplasms/therapy, Urinary Bladder Neoplasms/pathology, Neoplasm Invasiveness, Combined Modality Therapy, Neoplasm Recurrence, Local, Follow-Up Studies, Cystectomy/methods, Bladder preservation, Follow-up, Functional outcomes, Oncological outcomes, Trimodal treatment, Trimodality
Pubmed
Open Access
Yes
Create date
25/09/2024 10:04
Last modification date
26/09/2024 7:19
Usage data